Goserelin vs Leuprolide: Menopause Thyroid Function Changes in Breast Cancer

Menopause Thyroid Function Changes: What a New Breast Cancer Study Reveals About Hormones and the Thyroid

Nearly one in four women receiving goserelin for ovarian suppression showed abnormal thyroid function after six months of treatment, compared with just over one in nine of those on leuprolide. That finding comes from a 2026 retrospective cohort study published in Medwave by researchers at The First People’s Hospital of Changzhou, China — and it offers an unusually clear window into how aggressively suppressing reproductive hormones can disturb the thyroid, a concern that extends to natural and surgical menopause as well.

The Study: Two Ovarian-Suppressing Drugs, Two Different Side-Effect Patterns

Researchers led by J. Xu and Y. Tai followed 187 premenopausal women with hormone receptor-positive breast cancer who had undergone curative surgery. All received tamoxifen plus a gonadotropin-releasing hormone (GnRH) agonist to shut down ovarian function — a pharmaceutical version of menopause. Ninety women received leuprolide; 97 received goserelin.

After six months, both drugs performed almost identically at their primary job. Substantial estrogen suppression occurred in 88.89% of the leuprolide group and 92.78% of the goserelin group — a difference the researchers describe as statistically indistinguishable (risk difference −3.89%, 95% CI: −12.18% to 4.40%). Tumor marker CEA normalization rates were also comparable, at 93.33% and 92.78% respectively.

Safety told a different story. Liver function abnormalities appeared in 30.00% of leuprolide patients versus 13.40% of goserelin patients (p = 0.012), largely driven by abnormal aspartate aminotransferase (AST). Thyroid abnormalities ran the other way: only 76.29% of goserelin patients maintained normal thyroid function, compared with 88.89% on leuprolide (p = 0.018).

Why Hormonal Suppression Reaches the Thyroid

The thyroid and the reproductive axis are not separate systems. Estrogen influences thyroid hormone transport and conversion, and the hypothalamus — which produces GnRH — sits anatomically and functionally close to the circuits controlling thyroid-stimulating hormone release. When GnRH agonists like goserelin and leuprolide flood the system, they first overstimulate, then desensitize, the pituitary’s GnRH receptors. That desensitization can spill over into neighboring endocrine feedback loops, including the hypothalamic-pituitary-thyroid (HPT) axis.

TSH is the sensitive marker here. When the HPT axis is disturbed, TSH often shifts first — rising as the pituitary tries to compensate, or drifting outside the normal range as feedback signals get scrambled. This is exactly what the Changzhou team observed: the goserelin group’s thyroid disadvantage was driven mainly by a lower rate of normal TSH (83.51% vs. 93.33% on leuprolide).

Why goserelin affects the thyroid more while leuprolide stresses the liver remains unresolved. The authors point to differences in molecular structure between the two GnRH agonists, but the study was retrospective — treatment was not randomized — so confounding by patient characteristics or dosing schedules cannot be ruled out.

Why This Matters Beyond Breast Cancer Treatment

Most women never take goserelin or leuprolide. But the study’s broader lesson applies widely. Estrogen withdrawal — whether induced by drugs, surgery, or natural menopause — alters thyroid function in a meaningful subset of women, and the changes may not announce themselves with obvious symptoms. A mildly abnormal TSH can masquerade as “just menopause”: fatigue, cold intolerance, weight gain, brain fog, low mood.

This overlap has real clinical consequences. Women in perimenopause are already at elevated risk of thyroid dysfunction, particularly autoimmune hypothyroidism (Hashimoto’s thyroiditis), which peaks in midlife. Research on surgical menopause outcomes similarly shows that abrupt estrogen loss stresses multiple organ systems more than gradual decline. A woman whose thyroid quietly slips during this transition may attribute every symptom to hormones — and so might her clinician, unless someone orders a TSH test.

The mechanism also connects to symptom severity. Thyroid hormones regulate metabolism, temperature regulation, and mood — the same domains disrupted by falling estrogen. Symptoms related to hot flashes and neurokinin signaling can compound with thyroid dysfunction, making the combined picture harder to read without laboratory testing.

Practical Applications: Monitoring and Differentiation

• Ask for a TSH test if symptoms change. New fatigue, cold sensitivity, hair thinning, or unexplained weight gain during perimenopause warrant a thyroid panel, not just a hormone discussion.
• Timing matters. If you’re starting hormonal treatment — GnRH agonists, tamoxifen, or hormone therapy — a baseline TSH makes later changes interpretable. Reviews of hormone therapy safety increasingly recommend broader endocrine monitoring, and this study supports that.
• Don’t assume all symptoms are menopause. The Changzhou data show that hormonal suppression produced thyroid abnormalities in roughly one in five goserelin users — women who might otherwise have been told their symptoms were treatment side effects or menopausal transitions.
• For breast cancer patients and clinicians: the findings support individualized GnRH agonist selection. Women with existing liver conditions may favor goserelin; those with thyroid concerns may warrant closer monitoring on it.

Conclusion

Equal estrogen suppression does not mean equal whole-body effects. The Changzhou study shows two chemically similar GnRH agonists producing distinctly different organ-specific risks — goserelin stressing the thyroid, leuprolide stressing the liver. For anyone navigating perimenopause, induced menopause, or hormonal therapy, the takeaway is simple: the thyroid deserves a seat at the table, ideally with a TSH test before and during the transition.

Frequently Asked Questions

Does menopause itself cause thyroid problems?

Menopause doesn’t directly cause thyroid disease, but midlife estrogen fluctuations coincide with the peak age for thyroid dysfunction, especially hypothyroidism. Falling estrogen can also alter thyroid hormone transport and signaling, as seen in this study’s GnRH agonist data.

What thyroid test should I ask for during perimenopause?

A TSH (thyroid-stimulating hormone) test is the standard first-line screen. In this study, TSH was the parameter most often disrupted by hormonal suppression, making it the most sensitive marker to track.

Can thyroid symptoms be confused with menopause symptoms?

Yes. Fatigue, weight changes, low mood, temperature intolerance, and sleep problems overlap almost completely between hypothyroidism and menopause. A simple blood test can distinguish the two.

Is goserelin or leuprolide safer?

The study found both suppressed estrogen equally well. Leuprolide showed more liver abnormalities (30% vs. 13.4%), while goserelin showed more thyroid abnormalities (23.7% vs. 11.1%). Neither is universally safer; the choice should reflect individual liver and thyroid risk.

Sources:
https://pubmed.ncbi.nlm.nih.gov/42617170/
https://pubmed.ncbi.nlm.nih.gov/42607239/
https://pubmed.ncbi.nlm.nih.gov/42497321/
https://pubmed.ncbi.nlm.nih.gov/42394704/
https://pubmed.ncbi.nlm.nih.gov/41953700/